Natco Pharma is currently trading at Rs. 857.80, up by 13.50 points or 1.60% from its previous closing of Rs. 844.30 on the BSE.
The scrip opened at Rs. 880.00 and has touched a high and low of Rs. 920.00 and Rs. 849.10 respectively. So far 63843 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 750.45 on 24-Feb-2022.
Last one week high and low of the scrip stood at Rs. 920.00 and Rs. 822.85 respectively. The current market cap of the company is Rs. 15678.48 crore.
The promoters holding in the company stood at 48.86%, while Institutions and Non-Institutions held 30.34% and 20.80% respectively.
Natco Pharma along with its marketing partner Arrow International (an affiliate of Teva Pharmaceutical Industries) has launched the first generic version of Revlimid (Lenalidomide capsules) in 5mg, lOmg, lSmg, and 25mg strengths in the U.S. market.
The above strengths of lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment.
Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.